Cargando…
Cord serum metabolic signatures of future progression to immune-mediated diseases
Previous prospective studies suggest that progression to autoimmune diseases is preceded by metabolic dysregulation, but it is not clear which metabolic changes are disease-specific and which are common across multiple immune-mediated diseases. Here we investigated metabolic profiles in cord serum i...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10005901/ https://www.ncbi.nlm.nih.gov/pubmed/36915680 http://dx.doi.org/10.1016/j.isci.2023.106268 |
_version_ | 1784905190606897152 |
---|---|
author | Hyötyläinen, Tuulia Karthikeyan, Bagavathy Shanmugam Ghaffarzadegan, Tannaz Triplett, Eric W. Orešič, Matej Ludvigsson, Johnny |
author_facet | Hyötyläinen, Tuulia Karthikeyan, Bagavathy Shanmugam Ghaffarzadegan, Tannaz Triplett, Eric W. Orešič, Matej Ludvigsson, Johnny |
author_sort | Hyötyläinen, Tuulia |
collection | PubMed |
description | Previous prospective studies suggest that progression to autoimmune diseases is preceded by metabolic dysregulation, but it is not clear which metabolic changes are disease-specific and which are common across multiple immune-mediated diseases. Here we investigated metabolic profiles in cord serum in a general population cohort (All Babies In Southeast Sweden; ABIS), comprising infants who progressed to one or more immune-mediated diseases later in life: type 1 diabetes (n = 12), celiac disease (n = 28), juvenile idiopathic arthritis (n = 9), inflammatory bowel disease (n = 7), and hypothyroidism (n = 6); and matched controls (n = 270). We observed elevated levels of multiple triacylglycerols (TGs) an alteration in several gut microbiota related metabolites in the autoimmune groups. The most distinct differences were observed in those infants who later developed HT. The specific similarities observed in metabolic profiles across autoimmune diseases suggest that they share specific common metabolic phenotypes at birth that contrast with those of healthy controls. |
format | Online Article Text |
id | pubmed-10005901 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-100059012023-03-12 Cord serum metabolic signatures of future progression to immune-mediated diseases Hyötyläinen, Tuulia Karthikeyan, Bagavathy Shanmugam Ghaffarzadegan, Tannaz Triplett, Eric W. Orešič, Matej Ludvigsson, Johnny iScience Article Previous prospective studies suggest that progression to autoimmune diseases is preceded by metabolic dysregulation, but it is not clear which metabolic changes are disease-specific and which are common across multiple immune-mediated diseases. Here we investigated metabolic profiles in cord serum in a general population cohort (All Babies In Southeast Sweden; ABIS), comprising infants who progressed to one or more immune-mediated diseases later in life: type 1 diabetes (n = 12), celiac disease (n = 28), juvenile idiopathic arthritis (n = 9), inflammatory bowel disease (n = 7), and hypothyroidism (n = 6); and matched controls (n = 270). We observed elevated levels of multiple triacylglycerols (TGs) an alteration in several gut microbiota related metabolites in the autoimmune groups. The most distinct differences were observed in those infants who later developed HT. The specific similarities observed in metabolic profiles across autoimmune diseases suggest that they share specific common metabolic phenotypes at birth that contrast with those of healthy controls. Elsevier 2023-02-25 /pmc/articles/PMC10005901/ /pubmed/36915680 http://dx.doi.org/10.1016/j.isci.2023.106268 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Hyötyläinen, Tuulia Karthikeyan, Bagavathy Shanmugam Ghaffarzadegan, Tannaz Triplett, Eric W. Orešič, Matej Ludvigsson, Johnny Cord serum metabolic signatures of future progression to immune-mediated diseases |
title | Cord serum metabolic signatures of future progression to immune-mediated diseases |
title_full | Cord serum metabolic signatures of future progression to immune-mediated diseases |
title_fullStr | Cord serum metabolic signatures of future progression to immune-mediated diseases |
title_full_unstemmed | Cord serum metabolic signatures of future progression to immune-mediated diseases |
title_short | Cord serum metabolic signatures of future progression to immune-mediated diseases |
title_sort | cord serum metabolic signatures of future progression to immune-mediated diseases |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10005901/ https://www.ncbi.nlm.nih.gov/pubmed/36915680 http://dx.doi.org/10.1016/j.isci.2023.106268 |
work_keys_str_mv | AT hyotylainentuulia cordserummetabolicsignaturesoffutureprogressiontoimmunemediateddiseases AT karthikeyanbagavathyshanmugam cordserummetabolicsignaturesoffutureprogressiontoimmunemediateddiseases AT ghaffarzadegantannaz cordserummetabolicsignaturesoffutureprogressiontoimmunemediateddiseases AT triplettericw cordserummetabolicsignaturesoffutureprogressiontoimmunemediateddiseases AT oresicmatej cordserummetabolicsignaturesoffutureprogressiontoimmunemediateddiseases AT ludvigssonjohnny cordserummetabolicsignaturesoffutureprogressiontoimmunemediateddiseases |